IRIS
FEDERICO, Alessandro
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 25.063
NA - Nord America 11.974
AS - Asia 9.822
SA - Sud America 1.850
AF - Africa 151
OC - Oceania 29
Continente sconosciuto - Info sul continente non disponibili 5
Totale 48.894
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 15.583
US - Stati Uniti d'America 11.732
SG - Singapore 3.676
IE - Irlanda 2.406
IT - Italia 2.092
CN - Cina 1.940
BR - Brasile 1.527
HK - Hong Kong 1.504
UA - Ucraina 1.285
VN - Vietnam 1.134
GB - Regno Unito 1.062
DE - Germania 619
FI - Finlandia 499
FR - Francia 464
SE - Svezia 384
KR - Corea 333
TR - Turchia 289
GR - Grecia 257
IN - India 228
JP - Giappone 205
BD - Bangladesh 158
AR - Argentina 132
CA - Canada 96
NL - Olanda 90
AT - Austria 87
MX - Messico 83
PL - Polonia 63
IQ - Iraq 57
EC - Ecuador 55
ID - Indonesia 54
ZA - Sudafrica 49
ES - Italia 45
BE - Belgio 37
PK - Pakistan 34
AU - Australia 28
CO - Colombia 28
IR - Iran 26
PY - Paraguay 24
VE - Venezuela 23
UZ - Uzbekistan 22
PE - Perù 19
CL - Cile 18
EG - Egitto 18
MA - Marocco 17
MY - Malesia 17
SA - Arabia Saudita 17
AZ - Azerbaigian 15
DZ - Algeria 15
CZ - Repubblica Ceca 14
DO - Repubblica Dominicana 14
TH - Thailandia 14
TN - Tunisia 13
KE - Kenya 12
KZ - Kazakistan 12
UY - Uruguay 12
BO - Bolivia 11
NP - Nepal 11
HN - Honduras 9
LT - Lituania 9
TW - Taiwan 9
CH - Svizzera 8
CR - Costa Rica 8
JM - Giamaica 8
JO - Giordania 8
AL - Albania 7
ET - Etiopia 7
IL - Israele 7
MK - Macedonia 7
PT - Portogallo 7
RO - Romania 7
TT - Trinidad e Tobago 7
LK - Sri Lanka 6
SN - Senegal 6
AE - Emirati Arabi Uniti 5
BG - Bulgaria 5
GE - Georgia 5
GT - Guatemala 5
NO - Norvegia 5
CY - Cipro 4
DK - Danimarca 4
KG - Kirghizistan 4
PA - Panama 4
PH - Filippine 4
PS - Palestinian Territory 4
AM - Armenia 3
BA - Bosnia-Erzegovina 3
CI - Costa d'Avorio 3
EU - Europa 3
HR - Croazia 3
NG - Nigeria 3
OM - Oman 3
AO - Angola 2
BB - Barbados 2
BY - Bielorussia 2
HU - Ungheria 2
KH - Cambogia 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
MO - Macao, regione amministrativa speciale della Cina 2
NI - Nicaragua 2
Totale 48.867
Salva come PNG Salva come JPEG
Città #
Moscow 5.525
Dublin 2.400
Jacksonville 1.913
Hong Kong 1.479
Singapore 1.467
San Jose 1.312
Santa Clara 1.282
Chandler 1.229
Ashburn 539
Ho Chi Minh City 383
Princeton 377
Roxbury 311
Naples 310
Seoul 310
Beijing 303
Hefei 247
Hanoi 246
Ann Arbor 223
Cambridge 220
New York 207
Boardman 205
Dallas 183
Medford 168
Wilmington 158
Helsinki 149
Woodbridge 138
The Dalles 131
Bengaluru 118
São Paulo 107
Los Angeles 105
Caserta 99
Rome 96
Munich 93
Des Moines 89
Houston 84
San Mateo 77
Milan 72
Da Nang 66
Mountain View 66
Nanjing 63
Bremen 60
Dong Ket 54
Nuremberg 53
Orem 52
Haiphong 46
Amsterdam 45
Vienna 44
Council Bluffs 42
Düsseldorf 40
Napoli 40
Belo Horizonte 39
Tokyo 38
Rio de Janeiro 36
Atlanta 33
Brussels 33
Jinan 33
Kraków 33
Shanghai 32
Aversa 31
Brasília 31
Frankfurt am Main 31
Porto Alegre 31
Turku 31
Tianjin 30
Bologna 29
Norwalk 29
Curitiba 28
Paris 28
Shenyang 28
Guangzhou 27
Chicago 26
Potenza 26
Biên Hòa 25
San Francisco 25
London 24
Memphis 24
Bari 22
Chennai 22
Falkenstein 22
Guayaquil 22
Tashkent 22
Auburn Hills 21
Johannesburg 21
Montreal 21
Toronto 21
Mumbai 20
Thái Bình 20
Boydton 19
Brooklyn 19
Manchester 19
Mexico City 19
Campinas 18
Dhaka 17
Manaus 17
Quito 17
Salvador 17
Hangzhou 16
Palermo 16
Warsaw 16
Baku 15
Totale 24.266
Salva come PNG Salva come JPEG
Nome #
Sleisenger e Fordtran. Malattie gastrointestinali ed epatiche. Fisiopatologia, diagnosi e trattamento 373
Melanocortin 3,5 receptors immunohistochemical expression in colonic mucosa of inflammatory bowel disease patients: A matter of disease activity? 224
A Long-term Treatment with Silybin in Patients with Non-alcoholic Steatohepatitis Stimulates Catalase Activity in Human Endothelial Cells 221
Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis 209
Integrating Silybin and Sirtuin Related Pathways in Steatosis-Related Liver Diseases 198
Silybin for the treatment of metabolic oxidative alterations in patients with non-alcoholic steatohepatitis (NASH) 193
Intrafamilial spread of Helicobacter pylori infection 192
A "systems medicine" approach to the study of non-alcoholic fatty liver disease 186
Espressione del recettore dell’urotensina-II nell’adenocarcinoma del colon umano: studi in vitro ed in vivo. 181
Endocan Serum Levels in Patients with Non-Alcoholic Fatty Liver Disease with or without Type 2 Diabetes Mellitus: A Pilot Study 181
Adherence and Effects Derived from FODMAP Diet on Irritable Bowel Syndrome: A Real Life Evaluation of a Large Follow-Up Observation 180
Helicobacter pylory infection but not small intestinal bacterial overgrowth may play a pathogenic role in rosacea. 179
14-Day, High-Dose Acid Suppression, Non-Bismuth Quadruple Therapies (Hybrid vs. Concomitant) for Helicobacter pylori Infection: A Randomized Trial 179
A 60-Year-Old Woman with Primary Biliary Cholangitis and Crohn's Ileitis Following the Suspension of Ursodeoxycholic Acid 177
Autoimmune thyroid disease and neuroendocrine gastric tumors: early detection and efficacy of somatostatin analogue treatment. 176
A pilot study on the ability of clinoptilolite to absorb ethanol in vivo in healthy drinkers: effect of gender 174
Silybin-Induced Apoptosis Occurs in Parallel to the Increase of Ceramides Synthesis and miRNAs Secretion in Human Hepatocarcinoma Cells 173
Validity and reliability of the Italian version of the Chronic Liver Disease Questionnaire (CLDQ-I) for the assessment of health-related quality of life 173
Chronic inflammation and oxidative stress in human carcinogenesis 171
Alcohol and pathologies of the gastrointestinal tract, liver and pancreas 170
A probiotic treatment ameliorates CCl4-induced liver fibrosis in rats. 170
Just Drink a Glass of Water? Effects of Bicarbonate-Sulfate-Calcium-Magnesium Water on the Gut-Liver Axis 169
Crohn’s disease and skin 169
Antioxidant effects of Silybin, Silybin-phosphatidylcholine complex, and derivatives of Silibinin on in vitro cultured cells damaged by oxidative stress 167
A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and delta cohort 166
A case of hepatotoxicity caused by green tea 166
Alteration of haemostasis in non-metastatic gastric cancer 164
Alcoholic beverages and gastric epithelial cell viability: effect on oxidative stress-induced damage 164
Ameliorative effect of Silybin on bisphenol A induced oxidative stress, cell proliferation and steroid hormones oxidation in HepG2 cell cultures 164
A Facebook survey to obtain alcohol-related information by young people and adolescents. An Italian study 163
Telaprevir may induce adverse cutaneous reactions by a T cell immune-mediated mechanism 162
Composizione per il trattamento della sindrome metabolica e delle alterazioni metabolico-ossidative nei pazienti con steatoepatite non alcolica (NASH) 162
May chronic cough in chronic obstructive pulmonary disease be a contraindication of Percutaneous Endoscopic Gastrostomy placement: a case report 161
Attività citotossica della silibina su linee cellulari tumorali umane del tratto gastro-intestinale. 160
Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients 159
Oral microbiota and salivary levels of oral pathogens in gastro‐intestinal diseases: Current knowledge and exploratory study 159
Polydatin administration improves serum biochemical parameters and oxidative stress markers during chronic alcoholism: a pilot study 158
Activated protein C resistance in nonmetastatic gastric cancer patients. 158
BNT162b2 mRNA COVID-19 vaccine is safe in a setting of patients on biologic therapy with inflammatory bowel diseases: a monocentric real-life study 157
Long-term use of human albumin for the treatment of ascites in patients with hepatic cirrhosis: the interim analysis of the ANSWER study 157
A Combination of Microarray-Based Profiling and Biocomputational Analysis Identified miR331-3p and hsa-let-7d-5p as Potential Biomarkers of Ulcerative Colitis Progression to Colorectal Cancer 156
Alcoholic Consumption of Young Italians During the SARS-CoV-2 Pandemic 156
Hericium erinaceus, a medicinal fungus with a centuries-old history: Evidence in gastrointestinal diseases 154
AISF position paper on liver disease and pregnancy 153
'' Non alcoholic fatty liver disease and eNOS dysfunction in humans '' 153
A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease 152
Urotensin-II receptor expression in human colon adenocarcinoma: in vitro and in vivo studies. 151
Aggregazione piastrinica in pazienti con epatite cronica da HCV: studi in vitro. 151
A real-life study of new antiviral therapies in a high prevalence geographical area for hepatitis C virus infection 151
Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study 151
Gastrointestinal Hormones, Intestinal Microbiota and Metabolic Homeostasis in Obese Patients: Effect of Bariatric Surgery 150
Amelanotic metastatic melanoma of the stomach presenting with iron deficiency anemia 150
Tenofovir disoproxil fumarate monotherapy maintains HBV suppression achieved by a "de novo" combination of lamivudine-adefovir: a pilot study 149
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 149
Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments 148
Comparsa di pancreatite acuta ed epatite autoimmune in corso di trattamento con IFN: descrizione di un caso clinico. 147
Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota 147
Anorectal Function with High-Resolution Anorectal Manometry in Active Ulcerative Colitis and after Remission: A Pilot Study 146
Evaluation of the Efficacy and Safety of a Compound of Micronized Flavonoids in Combination With Vitamin C and Extracts of Centella asiatica, Vaccinium myrtillus, and Vitis vinifera for the Reduction of Hemorrhoidal Symptoms in Patients With Grade II and III Hemorrhoidal Disease: A Retrospective Real-Life Study 146
The bisphenol a induced oxidative stress in non-alcoholic fatty liver disease male patients: A clinical strategy to antagonize the progression of the disease 145
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort 145
How immunotherapy has changed the continuum of care in hepatocellular carcinoma 145
The use of bicarbonate-sulphate-calcium-magnesium and sodium-low drinkable water improves functional gastrointestinal symptoms in patients with non-alcoholic fatty liver disease: A prospective study 143
The urotensin-II receptor: A marker for staging and steroid outcome prediction in ulcerative colitis 143
Targeting the gut-brain axis for therapeutic adherence in patients with inflammatory bowel disease: a review on the role of psychotherapy 142
Skin Adverse Events During Dual And Triple Therapy For HCV-Related Cirrhosis 142
A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations 141
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 141
Non-bismuth and bismuth quadruple therapies based on previous clarithromycin exposure are as effective and safe in an area of high clarithromycin resistance: A real-life study 141
Chemical effect of bisphenol a on non-alcoholic fatty liver disease 141
An Italian survey on dietary habits and changes during the COVID-19 lockdown 141
Urotensin-II receptor is over-expressed in colon cancer cell lines and in colon carcinoma in humans. 140
Urotensin-II receptor: a new marker for the differentiation and the target in colon cancer? 140
Alcohol abuse affects nitric oxide production in patients with chronic liver disease. 137
Qualitative and quantitative evaluation of gut microbial populations in severely obese patients following bilio-intestinal bypass 137
The Lesson from the First Italian Lockdown: Impacts on Anxiety and Depressive Symptoms and Sleep Quality in Patients with Remission of Inflammatory Bowel Disease 137
Red cell distribution width/platelet ratio estimates the 3-year risk of decompensation in Metabolic Dysfunction-Associated Steatotic Liver Disease-induced cirrhosis 136
Light alcohol drinking and the risk of cancer development: a controversial relationship 135
The JAK-STAT Pathway as a Therapeutic Strategy in Cancer Patients with Immune Checkpoint Inhibitor-Induced Colitis: A Narrative Review 134
Vedolizumab as Rescue Therapy in Carboplatin-Gemcitabine-Induced Triggered Acute Severe Ulcerative Colitis Flare-Up 134
ITPase activity modulates the severity of anaemia in HCV-related cirrhosis treated with ribavirin-containing interferon-free regimens. 134
Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial 133
Cause di malnutrizione nel paziente neoplastico 133
Angiografia perfusionale con mdc di 2a generazione nella valutazione della efficacia necrotica delle terapie ablative percutanee (PAT): studio prospettico vs TC spirale. 133
Qualitative and Quantitative Evaluation of Dietary Intake in Patients with Non-Alcoholic Steatohepatitis 133
The Melanocortin System in Inflammatory Bowel Diseases: Insights into Its Mechanisms and Therapeutic Potentials 132
Alcohol associated liver disease 2020: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF) 132
Hericium erinaceus, in combination with natural flavonoid/alkaloid and B3/B8 vitamins, can improve inflammatory burden in Inflammatory bowel diseases tissue: an ex vivo study 130
Dysgeusia in MASLD-related advanced chronic liver disease (ACLD): a silent driver towards the "Bermuda" triangle of malnutrition-sarcopenia-frailty severely affecting prognosis 130
Obesità androide postmenopausale: ruolo del DHEA-S, didrotestosterone libero ed SHBG. 130
Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer 130
Trace elements and chronic liver diseases 129
Silybin–Phosphatidylcholine Complex Protects Human Gastric and Liver Cells from Oxidative Stress 129
Urotensin II receptor expression in patients with ulcerative colitis: a pilot study 129
Charting new AI education in gastroenterology: Cross-sectional evaluation of ChatGPT and perplexity AI in medical residency exam 128
Are Small Molecules Effective in Treating Inflammatory Pouch Disorders Following Ileal Pouch-Anal Anastomosis for Ulcerative Colitis? Here Is Where We Stand 128
The Role of Stress in Inflammatory Bowel Diseases 128
May ChatGPT be a tool producing medical information for common inflammatory bowel disease patients’ questions? An evidence-controlled analysis 127
Systemic Oxidative Balance Reflects the Liver Disease Progression Status for Primary Biliary Cholangitis (Pbc): The Narcissus Fountain 126
Considering a Janus kinase inhibitor in patients with concomitant ulcerative colitis and hidradenitis suppurativa/acne inversa: is it really a gamble? Hints from a case report 126
Totale 15.565
Salva come PNG Salva come JPEG
Categoria #
all - tutte 165.229
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 165.229
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021159 0 0 0 0 0 0 0 0 0 0 0 159
2021/20222.232 94 20 27 67 782 32 54 60 88 63 204 741
2022/20234.576 446 120 49 373 453 373 17 304 2.223 44 81 93
2023/20242.091 155 69 78 151 684 169 55 58 35 68 204 365
2024/20256.365 52 78 147 232 1.045 578 728 548 766 1.333 482 376
2025/202626.375 875 1.152 1.403 1.357 2.090 14.602 1.350 1.086 1.061 611 526 262
Totale 49.453